Karyopharm Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.30) Estimate, Sales $42.786M Beat $36.179M Estimate

Author: Benzinga Newsdesk | August 06, 2024 07:32am
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 31.03 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $42.786 million which beat the analyst consensus estimate of $36.179 million by 18.26 percent. This is a 13.86 percent increase over sales of $37.579 million the same period last year.

Posted In: KPTI